No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ADVM240517C2000
- 0.25
- 0.000.00%
15min DelayClose Mar 15 10:43 ET
0.00High0.00Low
0.00Open0.25Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover930.71%IV2.15%PremiumMay 17, 2024Expiry Date7.30Intrinsic Value100Multiplier5DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type0.9712Delta0.0060Gamma1.24Leverage Ratio-0.0608Theta0.0002Rho1.20Eff Leverage0.0008Vega
Intraday
- 5D
- 1D
News
Adverum Biotechnologies Reports Q1 2024 Results: A Detailed Look at Financials and Pipeline Progress
Express News | HC Wainwright & Co. Reiterates Buy on Adverum Biotechnologies, Maintains $30 Price Target
Express News | Adverum Biotechnologies Q1 2024 Adj EPS $(1.50) Misses $(1.40) Estimate
Express News | Adverum Biotechnologies Inc: $193.3 Mln in Cash, Cash Equivalents and Short-Term Investments Expected to Fund Operations Into Late 2025
Adverum Biotechnologies | 10-Q: Quarterly report
Adverum Biotechnologies 1Q Loss/Shr $1.50 >ADVM
Adverum Biotechnologies 1Q Loss/Shr $1.50 >ADVM
Comments
$Adverum Biotechnologies(ADVM.US$
NEWS
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
NEWS
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
$Adverum Biotechnologies(ADVM.US$ Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –
– Preliminary safety data support a favorable benefit-risk pr...
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –
– Preliminary safety data support a favorable benefit-risk pr...
1
2
$Adverum Biotechnologies(ADVM.US$ 2 insiders buy 200k cash in private placement, settlement Feb 8 the data release day. Lol, simple insider trading. Are they stupid? Anyway, there won’t be surprise for the data release, should be safe pass.
Just I am afriad the 1.2 private offering deal (typically 20% to 10% off to fair value) will pin the price to 1.4 to 1.6 area. Cashless warrant is bad for common investors. Also attract too many day traders. won’t last l...
Just I am afriad the 1.2 private offering deal (typically 20% to 10% off to fair value) will pin the price to 1.4 to 1.6 area. Cashless warrant is bad for common investors. Also attract too many day traders. won’t last l...
1
1
Let’s see.
$Adverum Biotechnologies(ADVM.US$Adverum Biotechnologies Has Agreed To Sell Approximately 106.25M Shares In A Private Placement At $1.20/Share With Gross Proceeds Of Approximately $127.5M; Pro Forma Cash And Investments Expected To Fund Current Operating Plan Into Late 2025
1
$Adverum Biotechnologies(ADVM.US$ 2 dollars?
2
3
Yes!!!Read more